MIRTAZAPINE - 45 45 MG
MIRTAZAPINE : 45 MG · DIN 02296691 · PRO DOC LIMITEE
Health Canada status: CANCELLED POST MARKET
What is MIRTAZAPINE - 45?
MIRTAZAPINE - 45 45 MG contains MIRTAZAPINE : 45 MG. It is listed in the Health Canada Drug Product Database under DIN 02296691, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 23-Jul-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MIRTAZAPINE - 45 used for?
Treatment of mild to moderate hypertension and chronic stable angina (effort-associated angina).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02296691 |
|---|---|
| Brand name | MIRTAZAPINE - 45 |
| Generic / active ingredient | MIRTAZAPINE : 45 MG |
| Manufacturer | PRO DOC LIMITEE |
| Strength | 45 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX11 MIRTAZAPINE |
| AHFS class | 28:16.04.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 23-Jul-2009 |
| Original market date | 2007-10-26 00:00:00 |
How is it administered?
Recommended starting dose is 20 mg or 30 mg once daily. Maximum daily dose is 90 mg. Swallow whole; do not crush or chew.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C and 30°C. Protect from light and humidity.
How is it supplied?
Available in blister packs and bottles of 100 tablets.
Contraindications
Hypersensitivity to nifedipine; pregnancy and lactation; cardiovascular shock; combination with rifampicin; Kock pouch.
Warnings and precautions
Caution in patients with hypotension, poor cardiac reserve, or severe gastrointestinal narrowing. May cause significant decrease in blood pressure.
Is MIRTAZAPINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AX11 MIRTAZAPINE. 31 of 64 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-MIRTAZAPINE | 15 MG | TABLET | APOTEX INC | MARKETED | DIN 02286610 |
| APO-MIRTAZAPINE | 30 MG | TABLET | APOTEX INC | MARKETED | DIN 02286629 |
| APO-MIRTAZAPINE | 45 MG | TABLET | APOTEX INC | MARKETED | DIN 02286637 |
| AURO-MIRTAZAPINE | 15 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02411695 |
| AURO-MIRTAZAPINE | 30 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02411709 |
| AURO-MIRTAZAPINE | 45 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02411717 |
| AURO-MIRTAZAPINE OD | 15 MG | TABLET (ORALLY DISINTEGRATING) | AURO PHARMA INC | MARKETED | DIN 02299801 |
| AURO-MIRTAZAPINE OD | 30 MG | TABLET (ORALLY DISINTEGRATING) | AURO PHARMA INC | MARKETED | DIN 02299828 |
| AURO-MIRTAZAPINE OD | 45 MG | TABLET (ORALLY DISINTEGRATING) | AURO PHARMA INC | MARKETED | DIN 02299836 |
| MIRTAZAPINE | 15 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02496666 |
Who else supplies MIRTAZAPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MIRTAZAPINE appears in 497 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.